AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (938.7 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Therapeutic implications of cancer stem cells in prostate cancer

Pinaki Banerjee1, Prachi Kapse2,*, Shehnaz Siddique3,*, Moumita Kundu3, Jasoda Choudhari4, Varshasnata Mohanty3, Diksha Malhotra3, Suresh W. Gosavi2, Rajesh N. Gacche4, Gopal C. Kundu3,5 ( )
National Centre for Cell Science, Savitribai Phule Pune University Campus, Pune 411007, India
School of Basic Medical Science, Savitribai Phule Pune University, Pune 411007, India
School of Biotechnology, KIIT Deemed to be University, Bhubaneswar 751024, India
Department of Biotechnology, Savitribai Phule Pune University, Pune 411007, India
Kalinga Institute of Medical Sciences (KIMS), KIIT Deemed to be University, Bhubaneswar 751024, India

*These authors contributed equally to this work.

Show Author Information

Abstract

Prostate cancer, one of the most frequently occurring cancers in men, is a heterogeneous disease involving multiple cell types within tumors. This tumor heterogeneity at least partly results from genomic instability leading to sub-clonal cellular differentiation. The differentiated cell populations originate from a small subset of cells with tumor-initiating and stem-like properties. These cells, termed prostate cancer stem cells (PCSCs), play crucial roles in disease progression, drug resistance, and relapse. This review discusses the origin, hierarchy, and plasticity of PCSCs; methods for isolation and enrichment of PCSCs; and various cellular and metabolic signaling pathways involved in PCSC induction and maintenance, as well as therapeutic targeting.

Keywords

prostate cancermetastasissignalingcancer stem cellstumor microenvironmenttumor growthEpithelial-mesenchymal transition

References

1

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71: 209-49.
Crossref Google Scholar
2

Marx A, Koopmann L, Höflmayer D, Büscheck F, Hube-Magg C, Steurer S, et al. Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer. Cancer Biol Med. 2021; 18: 245-55.
Crossref Google Scholar
3

Collins AT, Maitland NJ. Prostate cancer stem cells. Eur J Cancer. 2006; 42: 1213-8.
Crossref Google Scholar
4

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 57-70.
Crossref Google Scholar
5

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74.
Crossref Google Scholar
6

Fouad Y, Aanei C. Revisiting the hallmarks of cancer. Am J Cancer Res. 2017; 7: 1016-36.
Google Scholar
7

Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J Clin Oncol. 2008; 26: 2862-70.
Crossref Google Scholar
8

Wang ZA, Shen MM. Revisiting the concept of cancer stem cells in prostate cancer. Oncogene. 2011; 30: 1261-71.
Crossref Google Scholar
9

Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009; 138: 822-9.
Crossref Google Scholar
10

Marotta LLC, Polyak K. Cancer stem cells: a model in the making. Curr Opin Genet Dev. 2009; 19: 44-50.
Crossref Google Scholar
11

Menendez J, Joven J, Cufí S, Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, et al. The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. Cell Cycle. 2013; 12: 1166-79.
Crossref Google Scholar
12

Ahmad F, Cherukuri MK, Choyke PL. Metabolic reprogramming in prostate cancer. Br J Cancer. 2021; 125: 1185-96.
Crossref Google Scholar
13

Yun EJ, Lo UG, Hsieh JT. The evolving landscape of prostate cancer stem cell: therapeutic implications and future challenges. Asian J Urol. 2016; 3: 203-10.
Crossref Google Scholar
14

Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev. 2018; 32: 1105-40.
Crossref Google Scholar
15

Romańska-Knight H, Abel P. REVIEW ARTICLES Prostate cancer stem cells. Cent Eur J Urol. 2011; 64: 196-200.
Crossref Google Scholar
16

Zhang D, Zhao S, Li X, Kirk JS, Tang DG. Prostate luminal progenitor cells in development and cancer. Trends Cancer. 2018; 4: 769-83.
Crossref Google Scholar
17

Avgustinova A, Benitah SA. The epigenetics of tumour initiation: cancer stem cells and their chromatin. Curr Opin Genet Dev. 2016; 36: 8-15.
Crossref Google Scholar
18

Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017; 14: 611-29.
Crossref Google Scholar
19

Yun EJ, Zhou J, Lin CJ, Hernandez E, Fazli L, Gleave M, et al. Targeting cancer stem cells in castration-resistant prostate cancer. Clin Cancer Res. 2016; 22: 670-9.
Crossref Google Scholar
20

Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci. 2004; 117: 3539-45.
Crossref Google Scholar
21

Taylor RA, Toivanen R, Frydenberg M, Pedersen J, Harewood L, Collins AT, et al. Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status. Stem Cells. 2012; 30: 1087-96.
Crossref Google Scholar
22

Liu AY, Nelson PS, van den Engh G, Hood L. Human prostate epithelial cell-type cDNA libraries and prostate expression patterns. Prostate. 2002; 50: 92-103.
Crossref Google Scholar
23

Kyprianou N, Isaacs JT. Identification of a cellular receptor for transforming growth factor-β in rat ventral prostate and its negative regulation by androgens*. Endocrinology. 1988; 123: 2124-31.
Crossref Google Scholar
24

De Marzo AM, Meeker AK, Epstein JI, Coffey DS. Prostate stem cell compartments. Am J Pathol. 1998; 153: 911-9.
Crossref Google Scholar
25

Choi N, Zhang B, Zhang L, Ittmann M, Xin L. Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell. 2012; 21: 253-65.
Crossref Google Scholar
26

Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell of origin for human prostate cancer. Science. 2010; 329: 568-71.
Crossref Google Scholar
27

Smith BA, Sokolov A, Uzunangelov V, Baertsch R, Newton Y, Graim K, et al. A basal stem cell signature identifies aggressive prostate cancer phenotypes. Proc Natl Acad Sci. 2015; 112: E6544-52.
Crossref Google Scholar
28

Liu AY, True LD, LaTray L, Nelson PS, Ellis WJ, Vessella RL, et al. Cell–cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci. 1997; 94: 10705-10.
Crossref Google Scholar
29

Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, SchneiderBroussard R, et al. Prostate cancer stem/progenitor cells: identification, characterization, and implications: prostate cancer stem/progenitor cells. Mol Carcinog. 2007; 46: 1-14.
Crossref Google Scholar
30

Wang X, de Julio MK, Economides KD, Walker D, Yu H, Halili MV, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature. 2009; 461: 495-500.
Crossref Google Scholar
31

Wang JCY. Good cells gone bad: the cellular origins of cancer. Trends Mol Med. 2010; 16: 145-51.
Crossref Google Scholar
32

Pomerantz MM, Qiu X, Zhu Y, Takeda DY, Pan W, Baca SC, et al. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat Genet. 2020; 52: 790-9.
Crossref Google Scholar
33

Yamada Y, Beltran H. Clinical and biological features of neuroendocrine prostate cancer. Curr Oncol Rep. 2021; 23: 15.
Crossref Google Scholar
34

Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010; 467: 1109-13.
Crossref Google Scholar
35

Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR, et al. The PSA-/lo prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell. 2012; 10: 556-69.
Crossref Google Scholar
36

Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44 + α2β1 + cell population is enriched in tumor-initiating cells. Cancer Res. 2007; 67: 6796-805.
Crossref Google Scholar
37

Shibata M, Shen MM. Stem cells in genetically-engineered mouse models of prostate cancer. Endocr Relat Cancer. 2015; 22: T199-208.
Crossref Google Scholar
38

Lo UG, Lee CF, Lee MS, Hsieh JT. The role and mechanism of epithelial-to-mesenchymal transition in prostate cancer progression. Int J Mol Sci. 2017; 18: 2079.
Crossref Google Scholar
39

Drago D, Andolfo A, Mosca E, Orro A, Nocera L, Cucchiara V, et al. A novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer. Cancer Biol Med. 2021; 18: 604-15.
Crossref Google Scholar
40

Schröder F, Crawford ED, Axcrona K, Payne H, Keane TE. Androgen deprivation therapy: past, present and future: androgen deprivation therapy: past, present and future. BJU Int. 2012; 109: 1-12.
Crossref Google Scholar
41

Tang DG. Understanding and targeting prostate cancer cell heterogeneity and plasticity. Semin Cancer Biol. 2022; 82: 68-93.
Crossref Google Scholar
42

Parol-Kulczyk M, Gzil A, Ligmanowska J, Grzanka D. Prognostic significance of SDF-1 chemokine and its receptors CXCR4 and CXCR7 involved in EMT of prostate cancer. Cytokine. 2022; 150: 155778.
Crossref Google Scholar
43

Joesting MS, Perrin S, Elenbaas B, Fawell SE, Rubin JS, Franco OE, et al. Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res. 2005; 65: 10423-30.
Crossref Google Scholar
44

Shiota M, Fujimoto N, Matsumoto T, Tsukahara S, Nagakawa S, Ueda S, et al. Differential impact of TGFB1 variation by metastatic status in androgen-deprivation therapy for prostate cancer. Front Oncol. 2021; 11: 697955.
Crossref Google Scholar
 
Agarwal JR, Zambidis ET. The role of an NFκB-STAT3 signaling axis in regulating the induction and maintenance of the pluripotent state. In: Atwood CS, Meethal SV, editors. Pluripotent stem cell biology - advances in mechanisms, methods and models. InTech; 2014.
Crossref
46

Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol. 2018; 15: 271-86.
Crossref Google Scholar
47

Skvortsov S, Skvortsova Ⅱ, Tang DG, Dubrovska A. Concise review: prostate cancer stem cells: current understanding. Stem Cells. 2018; 36: 1457-74.
Crossref Google Scholar
48

Liu WH, Qian NS, Li R, Dou KF. Replacing Hoechst33342 with Rhodamine123 in isolation of cancer stem-like cells from the MHCC97 cell line. Toxicol In Vitro. 2010; 24: 538-45.
Crossref Google Scholar
49

Vidal SJ, Quinn SA, de la Iglesia-Vicente J, Bonal DM, RodriguezBravo V, Firpo-Betancourt A, et al. Isolation of cancer stem cells from human prostate cancer samples. J Vis Exp. 2014; 85: 51332.
Crossref Google Scholar
50

Sheng X, Li Z, Wang DL, Li WB, Luo Z, Chen KH, et al. Isolation and enrichment of PC-3 prostate cancer stem-like cells using MACS and serum-free medium. Oncol Lett. 2013; 5: 787-92.
Crossref Google Scholar
51

Kim WT, Ryu CJ. Cancer stem cell surface markers on normal stem cells. BMB Rep. 2017; 50: 285-98.
Crossref Google Scholar
52

Tang B, Raviv A, Esposito D, Flanders KC, Daniel C, Nghiem BT, et al. A flexible reporter system for direct observation and isolation of cancer stem cells. Stem Cell Rep. 2015; 4: 155-69.
Crossref Google Scholar
53

Thiagarajan PS, Hitomi M, Hale JS, Alvarado AG, Otvos B, Sinyuk M, et al. Development of a fluorescent reporter system to delineate cancer stem cells in triple-negative breast cancer. Stem Cells. 2015; 33: 2114-25.
Crossref Google Scholar
54

Jeter CR, Liu B, Liu X, Chen X, Liu C, Calhoun-Davis T, et al. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene. 2011; 30: 3833-45.
Crossref Google Scholar
55

Chen X, Rycaj K, Liu X, Tang DG. New insights into prostate cancer stem cells. Cell Cycle. 2013; 12: 579-86.
Crossref Google Scholar
56

Li Q, Rycaj K, Chen X, Tang DG. Cancer stem cells and cell size: a causal link? Semin Cancer Biol. 2015; 35: 191-9.
Crossref Google Scholar
57

Chen YC, Ingram PN, Fouladdel S, McDermott SP, Azizi E, Wicha MS, et al. High-throughput single-cell derived sphere formation for cancer stem-like cell identification and analysis. Sci Rep. 2016; 6: 27301.
Crossref Google Scholar
58

Matsui WH. Cancer stem cell signaling pathways. Medicine (Baltimore). 2016; 95: S8-19.
Crossref Google Scholar
59

Wu J, Cang S, Liu C, Ochiai W, Chiao JW. Development of human prostate cancer stem cells involves epigenomic alteration and PI3K/AKT pathway activation. Exp Hematol Oncol. 2020; 9: 12.
Crossref Google Scholar
60

Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, GarcíaEcheverría C, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci. 2009; 106: 268-73.
Crossref Google Scholar
61

Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, et al. Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis. 2013; 4: e875-e875.
Crossref Google Scholar
62

Ma B, Shao H, Jiang X, Wang Z, Wu CC, Whaley D, et al. Akt isoforms differentially provide for chemoresistance in prostate cancer. Cancer Biol Med. 2021; 19: 635-50.
Crossref Google Scholar
63

Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007; 26: 3279-90.
Crossref Google Scholar
64

Rybak AP, Ingram AJ, Tang D. Propagation of human prostate cancer stem-like cells occurs through EGFR-mediated ERK activation. PLoS ONE. 2013; 8: e61716.
Crossref Google Scholar
65

Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, et al. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 2012; 72: 1878-89.
Crossref Google Scholar
66

Ko J, Meyer AN, Haas M, Donoghue DJ. Characterization of FGFR signaling in prostate cancer stem cells and inhibition via TKI treatment. Oncotarget. 2021; 12: 22-36.
Crossref Google Scholar
67

Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, Gao AC. Stat3 activation in prostatic carcinomas. The Prostate. 2002; 51: 241-6.
Crossref Google Scholar
68

Schroeder A, Herrmann A, Cherryholmes G, Kowolik C, Buettner R, Pal S, et al. Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Res. 2014; 74: 1227-37.
Crossref Google Scholar
69

Kroon P, Berry PA, Stower MJ, Rodrigues G, Mann VM, Simms M, et al. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res. 2013; 73: 5288-98.
Crossref Google Scholar
70

Carvalho FLF, Simons BW, Eberhart CG, Berman DM. Notch signaling in prostate cancer: a moving target: notch signaling in prostate cancer. Prostate. 2014; 74: 933-45.
Crossref Google Scholar
71

Espinoza I, Miele L. Deadly crosstalk: notch signaling at the intersection of EMT and cancer stem cells. Cancer Lett. 2013; 341: 41-5.
Crossref Google Scholar
72

Cochrane C, Szczepny A, Watkins D, Cain J. Hedgehog signaling in the maintenance of cancer stem cells. Cancers. 2015; 7: 1554-85.
Crossref Google Scholar
73

Shaw A, Bushman W. Hedgehog signaling in the prostate. J Urol. 2007; 177: 832-8.
Crossref Google Scholar
74

Datta S, Datta MW. Sonic Hedgehog signaling in advanced prostate cancer. Cell Mol Life Sci. 2006; 63: 435-48.
Crossref Google Scholar
75

Acikgoz E, Mukhtarova G, Alpay A, Avci CB, Bagca BG, Oktem G. Sonic hedgehog signaling is associated with resistance to zoledronic acid in CD133high/CD44high prostate cancer stem cells. Mol Biol Rep. 2021; 48: 3567-78.
Crossref Google Scholar
76

Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017; 36: 1461-73.
Crossref Google Scholar
77

Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res. 2009; 19: 683-97.
Crossref Google Scholar
78

Zhang K, Guo Y, Wang X, Zhao H, Ji Z, Cheng C, et al. WNT/β-Catenin directs self-renewal symmetric cell division of hTERT high prostate cancer stem cells. Cancer Res. 2017; 77: 2534-47.
Crossref Google Scholar
79

Murillo-Garzón V, Kypta R. WNT signalling in prostate cancer. Nat Rev Urol. 2017; 14: 683-96.
Crossref Google Scholar
80

Du H, Wang X, Dong R, Hu D, Xiong Y. miR-601 inhibits proliferation, migration and invasion of prostate cancer stem cells by targeting KRT5 to inactivate the Wnt signaling pathway. Int J Clin Exp Pathol. 2019; 12: 4361-79.
Google Scholar
81

Mo J, Park HW, Guan K. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 2014; 15: 642-56.
Crossref Google Scholar
82

Machado-Neto JA, Lazarini M, Favaro P, Franchi GC, Nowill AE, Saad STO, et al. ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells. Exp Cell Res. 2014; 324: 137-45.
Crossref Google Scholar
83

Jiang N, Ke B, Hjort-Jensen K, Iglesias-Gato D, Wang Z, Chang P, et al. YAP1 regulates prostate cancer stem cell-like characteristics to promote castration resistant growth. Oncotarget. 2017; 8: 115054-67.
Crossref Google Scholar
84

Liu N, Mei L, Fan X, Tang C, Ji X, Hu X, et al. Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway. Cancer Lett. 2016; 378: 38-50.
Crossref Google Scholar
85

Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, EbrahimiKalan A, Jaymand M, et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020; 18: 59.
Crossref Google Scholar
86

Nieto MA, Huang RYJ, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016; 166: 21-45.
Crossref Google Scholar
87

Craene BD, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013; 13: 97-110.
Crossref Google Scholar
88

Melo CM, Vidotto T, Chaves LP, Lautert-Dutra W, dos Reis RB, Squire JA. The role of somatic mutations on the immune response of the tumor microenvironment in prostate cancer. Int J Mol Sci. 2021; 22: 9550.
Crossref Google Scholar
89

Lau EYT, Ho NPY, Lee TKW. Cancer stem cells and their microenvironment: biology and therapeutic implications. Stem Cells Int. 2017; 2017: 3714190.
Crossref Google Scholar
90

Liao CP, Adisetiyo H, Liang M, Roy-Burman P. Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. Cancer Res. 2010; 70: 7294-303.
Crossref Google Scholar
91

Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L, et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010; 70: 6945-56.
Crossref Google Scholar
92

Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005; 115: 911-9.
Crossref Google Scholar
93

Tang KD, Liu J, Jovanovic L, An J, Hill MM, Vela I, et al. Adipocytes promote prostate cancer stem cell self-renewal through amplification of the cholecystokinin autocrine loop. Oncotarget. 2016; 7: 4939-48.
Crossref Google Scholar
94

Chen Y, Tan W, Wang C. Tumor-associated macrophage-derived cytokines enhance cancer stem-like characteristics through epithelial–mesenchymal transition. Onco Targets Ther. 2018; 11: 3817-26.
Crossref Google Scholar
95

Huang R, Wang S, Wang N, Zheng Y, Zhou J, Yang B, et al. CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating β-catenin/STAT3 signaling. Cell Death Dis. 2020; 11: 234.
Crossref Google Scholar
96

Zhang C, Zhi WI, Lu H, Samanta D, Chen I, Gabrielson E, et al. Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells. Oncotarget. 2016; 7: 64527-42.
Crossref Google Scholar
97

Bae KM, Dai Y, Vieweg J, Siemann DW. Hypoxia regulates SOX2 expression to promote prostate cancer cell invasion and sphere formation. Am J Cancer Res. 2016; 6: 1078-88.
Google Scholar
98

Koukourakis MI, Kakouratos C, Kalamida D, Bampali Z, Mavropoulou S, Sivridis E, et al. Hypoxia-inducible proteins HIF1α and lactate dehydrogenase LDH5, key markers of anaerobic metabolism, relate with stem cell markers and poor post-radiotherapy outcome in bladder cancer. Int J Radiat Biol. 2016; 92: 353-63.
Crossref Google Scholar
99

Marhold M, Tomasich E, El-Gazzar A, Heller G, Spittler A, Horvat R, et al. HIF1α Regulates mTOR signaling and viability of prostate cancer stem cells. Mol Cancer Res. 2015; 13: 556-64.
Crossref Google Scholar
100

Maeda K, Ding Q, Yoshimitsu M, Kuwahata T, Miyazaki Y, Tsukasa K, et al. CD133 Modulate HIF-1α expression under hypoxia in EMT phenotype pancreatic cancer stem-like cells. Int J Mol Sci. 2016; 17: 1025.
Crossref Google Scholar
101

DeBerardinis RJ, Thompson CB. Cellular metabolism and disease: what do metabolic outliers teach us? Cell. 2012; 148: 1132-44.
Crossref Google Scholar
102

Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016; 23: 27-47.
Crossref Google Scholar
103

DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016; 2: e1600200.
Crossref Google Scholar
104

Bader DA, Hartig SM, Putluri V, Foley C, Hamilton MP, Smith EA, et al. Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. Nat Metab. 2019; 1: 70-85.
Crossref Google Scholar
105

Verze P, Cai T, Lorenzetti S. The role of the prostate in male fertility, health and disease. Nat Rev Urol. 2016; 13: 379-86.
Crossref Google Scholar
106

Barron ESG, Huggins C. The metabolism of the prostate: transamination and citric acid. J Urol. 1946; 55: 385-90.
Crossref Google Scholar
107

Mycielska ME, Patel A, Rizaner N, Mazurek MP, Keun H, Patel A, et al. Citrate transport and metabolism in mammalian cells: prostate epithelial cells and prostate cancer. BioEssays. 2009; 31: 10-20.
Crossref Google Scholar
108

Costello LC, Liu Y, Franklin RB, Kennedy MC. Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells. J Biol Chem. 1997; 272: 28875-81.
Crossref Google Scholar
109

Düvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010; 39: 171-83.
Crossref Google Scholar
110

Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. Oncogene. 2005; 24: 6314-22.
Crossref Google Scholar
111

Wang W, Fridman A, Blackledge W, Connelly S, Wilson IA, Pilz RB, et al. The phosphatidylinositol 3-Kinase/Akt cassette regulates purine nucleotide synthesis. J Biol Chem. 2009; 284: 3521-8.
Crossref Google Scholar
112

Latonen L, Afyounian E, Jylhä A, Nättinen J, Aapola U, Annala M, et al. Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. Nat Commun. 2018; 9: 1176.
Crossref Google Scholar
113

Shao Y, Ye G, Ren S, Piao HL, Zhao X, Lu X, et al. Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer: metabolomics and transcriptomics profiles in prostate cancer. Int J Cancer. 2018; 143: 396-407.
Crossref Google Scholar
114

Wang Q, Tiffen J, Bailey CG, Lehman ML, Ritchie W, Fazli L, et al. Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. JNCI J Natl Cancer Inst. 2013; 105: 1463-73.
Crossref Google Scholar
115

Wang Q, Bailey CG, Ng C, Tiffen J, Thoeng A, Minhas V, et al. Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Res. 2011; 71: 7525-36.
Crossref Google Scholar
116

Karthaus WR, Hofree M, Choi D, Linton EL, Turkekul M, Bejnood A, et al. Regenerative potential of prostate luminal cells revealed by single-cell analysis. Science. 2020; 368: 497-505.
Crossref Google Scholar
117

Savir-Baruch B, Zanoni L, Schuster DM. Imaging of prostate cancer using fluciclovine. Urol Clin North Am. 2018; 45: 489-502.
Crossref Google Scholar
118

Okudaira H, Oka S, Ono M, Nakanishi T, Schuster DM, Kobayashi M, et al. Accumulation of trans-1-amino-3-[18F]Fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters. Mol Imaging Biol. 2014; 16: 756-64.
Crossref Google Scholar
119

Zaidi N, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV, Smans K. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res. 2013; 52: 585-9.
Crossref Google Scholar
120

Clarke NW, Brown MD. The influence of lipid metabolism on prostate cancer development and progression: is it time for a closer look? Eur Urol. 2007; 52: 3-4.
Crossref Google Scholar
121

Suburu J, Chen YQ. Lipids and prostate cancer. Prostaglandins Other Lipid Mediat. 2012; 98: 1-10.
Crossref Google Scholar
122

Yue S, Li J, Lee SY, Lee HJ, Shao T, Song B, et al. Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab. 2014; 19: 393-406.
Crossref Google Scholar
123

Gazi E, Gardner P, Lockyer NP, Hart CA, Brown MD, Clarke NW. Direct evidence of lipid translocation between adipocytes and prostate cancer cells with imaging FTIR microspectroscopy. J Lipid Res. 2007; 48: 1846-56.
Crossref Google Scholar
124

Swinnen JV, Roskams T, Joniau S, van Poppel H, Oyen R, Baert L, et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer. 2002; 98: 19-22.
Crossref Google Scholar
125

Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 2006; 9: 230-4.
Crossref Google Scholar
126

Lloyd MD, Yevglevskis M, Lee GL, Wood PJ, Threadgill MD, Woodman TJ. α-Methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S. Prog Lipid Res. 2013; 52: 220-30.
Crossref Google Scholar
127

Zha S, Ferdinandusse S, Denis S, Wanders RJ, Ewing CM, Luo J, et al. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res. 2003; 63: 7365-76.
Google Scholar
128

Ahmad F, Patrick S, Sheikh T, Sharma V, Pathak P, Malgulwar PB, et al. Telomerase reverse transcriptase (TERT) - enhancer of zeste homolog 2 (EZH2) network regulates lipid metabolism and DNA damage responses in glioblastoma. J Neurochem. 2017; 143: 671-83.
Crossref Google Scholar
129

Van de Sande T, Roskams T, Lerut E, Joniau S, Van Poppel H, Verhoeven G, et al. High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. J Pathol. 2005; 206: 214-9.
Crossref Google Scholar
130

Guo D, Bell E, Mischel P, Chakravarti A. Targeting SREBP-1-driven lipid metabolism to treat cancer. Curr Pharm Des. 2014; 20: 2619-26.
Crossref Google Scholar
131

Ayyagari VN, Wang X, Diaz-Sylvester PL, Groesch K, Brard L. Assessment of acyl-CoA cholesterol acyltransferase (ACAT-1) role in ovarian cancer progression—an in vitro study. PLoS One. 2020; 15: e0228024.
Crossref Google Scholar
132

Wu X, Daniels G, Lee P, Monaco ME. Lipid metabolism in prostate cancer. Am J Clin Exp Urol. 2014; 2: 111-20.
Google Scholar
133

Roy M, Kung HJ, Ghosh PM. Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am J Cancer Res. 2011; 1: 542-61.
Google Scholar
134

Svensson RU, Parker SJ, Eichner LJ, Kolar MJ, Wallace M, Brun SN, et al. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. Nat Med. 2016; 22: 1108-19.
Crossref Google Scholar
135

Prescott JL, Blok L, Tindall DJ. Isolation and androgen regulation of the human homeobox cDNA, NKX3.1. Prostate. 1998; 35: 71-80.
Crossref Google Scholar
136

Lao L, Franklin RB, Costello LC. High-affinityL-aspartate transporter in prostate epithelial cells that is regulated by testosterone. Prostate. 1993; 22: 53-63.
Crossref Google Scholar
137

Swinnen JV, Van Veldhoven PP, Esquenet M, Heyns W, Verhoeven G. Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology. 1996; 137: 4468-74.
Crossref Google Scholar
138

Audet-Walsh É, Yee T, McGuirk S, Vernier M, Ouellet C, St-Pierre J, et al. Androgen-dependent repression of ERRγ reprograms metabolism in prostate cancer. Cancer Res. 2017; 77: 378-89.
Crossref Google Scholar
139

Tsouko E, Khan AS, White MA, Han JJ, Shi Y, Merchant FA, et al. Regulation of the pentose phosphate pathway by an androgen receptor–mTOR-mediated mechanism and its role in prostate cancer cell growth. Oncogenesis. 2014; 3: e103-e103.
Crossref Google Scholar
140

Patra KC, Hay N. The pentose phosphate pathway and cancer. Trends Biochem Sci. 2014; 39: 347-54.
Crossref Google Scholar
141

Ather MH, Abbas F, Faruqui N, Israr M, Pervez S. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol. 2008; 8: 21.
Crossref Google Scholar
142

Choi YJ, Lin CP, Ho JJ, He X, Okada N, Bu P, et al. miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nat Cell Biol. 2011; 13: 1353-60.
Crossref Google Scholar
143

Kareta MS, Gorges LL, Hafeez S, Benayoun BA, Marro S, Zmoos AF, et al. Inhibition of pluripotency networks by the Rb tumor suppressor restricts reprogramming and tumorigenesis. Cell Stem Cell. 2015; 16: 39-50.
Crossref Google Scholar
144

Schvartzman JM, Thompson CB, Finley LWS. Metabolic regulation of chromatin modifications and gene expression. J Cell Biol. 2018; 217: 2247-59.
Crossref Google Scholar
145

Wang HJ, Pochampalli M, Wang LY, Zou JX, Li PS, Hsu SC, et al. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. Oncogene. 2019; 38: 17-32.
Crossref Google Scholar
146

Reina-Campos M, Linares JF, Duran A, Cordes T, L’Hermitte A, Badur MG, et al. Increased serine and one-carbon pathway metabolism by PKCλ/ι deficiency promotes neuroendocrine prostate cancer. Cancer Cell. 2019; 35: 385-400.e9.
Crossref Google Scholar
147

Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009; 15: 6479-83.
Crossref Google Scholar
148

Liu R, Liu C, Zhang D, Liu B, Chen X, Rycaj K, et al. miR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells. Oncotarget. 2016; 7: 56628-42.
Crossref Google Scholar
149

Civenni G, Malek A, Albino D, Garcia-Escudero R, Napoli S, Di Marco S, et al. RNAi-Mediated silencing of myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer. Cancer Res. 2013; 73: 6816-27.
Crossref Google Scholar
150

Sharifi N, Kawasaki BT, Hurt EM. Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy. Cancer Biol Ther. 2006; 5: 901-6.
Crossref Google Scholar
151

Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012; 487: 239-43.
Crossref Google Scholar
152

Semenas J, Allegrucci C, Boorjian SA, Mongan NP, Liao Persson J. Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets. 2012; 13: 1308-23.
Crossref Google Scholar
153

Ni J, Cozzi P, Hao J, Duan W, Graham P, Kearsley J, et al. Cancer stem cells in prostate cancer chemoresistance. Curr Cancer Drug Targets. 2014; 14: 225-40.
Crossref Google Scholar
154

Bishop JL, Davies A, Ketola K, Zoubeidi A. Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. Endocr Relat Cancer. 2015; 22: R165-82.
Crossref Google Scholar
155

Singh P, Uzgare A, Litvinov I, Denmeade SR, Isaacs JT. Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr Relat Cancer. 2006; 13: 653-66.
Crossref Google Scholar
156

Zhang L, Jiao M, Li L, Wu D, Wu K, Li X, et al. Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties. J Cancer Res Clin Oncol. 2012; 138: 675-86.
Crossref Google Scholar
157

Njar VCO, Brodie AMH. Discovery and development of galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J Med Chem. 2015; 58: 2077-87.
Crossref Google Scholar
158

Adeniji AO, Chen M, Penning TM. AKR1C3 as a target in castrate resistant prostate cancer. J Steroid Biochem Mol Biol. 2013; 137: 136-49.
Crossref Google Scholar
159

De Leon JT, Iwai A, Feau C, Garcia Y, Balsiger HA, Storer CL, et al. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc Natl Acad Sci. 2011; 108: 11878-83.
Crossref Google Scholar
160

Kregel S, Kiriluk KJ, Rosen AM, Cai Y, Reyes EE, Otto KB, et al. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One. 2013; 8: e53701.
Crossref Google Scholar
161

Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, et al. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene. 2012; 31: 4759-67.
Crossref Google Scholar
162

Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, et al. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One. 2011; 6: e27970.
Crossref Google Scholar
163

Lu J, der Steen TV, Tindall DJ. Are androgen receptor variants a substitute for the full-length receptor? Nat Rev Urol. 2015; 12: 137-44.
Crossref Google Scholar
164

Lu C, Luo J. Decoding the androgen receptor splice variants. Transl Androl Urol. 2013; 2: 178-186.
Google Scholar
165

Kong D, Sethi S, Li Y, Chen W, Sakr WA, Heath E, et al. Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes: AR variants are linked with PCa progression. Prostate. 2015; 75: 161-74.
Crossref Google Scholar
166

Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci. 2013; 110: 972-7.
Crossref Google Scholar
167

Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci. 2011; 108: 1397-402.
Crossref Google Scholar
168

Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 2011; 71: 3196-201.
Crossref Google Scholar
169

Mayer MJ, Klotz LH, Venkateswaran V. Metformin and prostate cancer stem cells: a novel therapeutic target. Prostate Cancer Prostatic Dis. 2015; 18: 303-9.
Crossref Google Scholar
170

Vallianou NG, Evangelopoulos A, Kazazis C. Metformin and cancer. Rev Diabet Stud. 2013; 10: 228-35.
Crossref Google Scholar
171

Bilen MA, Lin SH, Tang DG, Parikh K, Lee MH, Yeung SC, et al. Maintenance therapy containing metformin and/or zyflamend for advanced prostate cancer: a case series. Case Rep Oncol Med. 2015; 2015: 471861.
Crossref Google Scholar
172

Li Y, Wicha MS, Schwartz SJ, Sun D. Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem. 2011; 22: 799-806.
Crossref Google Scholar
173

Scarpa ES, Ninfali P. Phytochemicals as innovative therapeutic tools against cancer stem cells. Int J Mol Sci. 2015; 16: 15727-42.
Crossref Google Scholar
174

Teiten MH, Gaigneaux A, Chateauvieux S, Billing AM, Planchon S, Fack F, et al. Identification of differentially expressed proteins in curcumin-treated prostate cancer cell lines. OMICS J Integr Biol. 2012; 16: 289-300.
Crossref Google Scholar
175

Botchkina GI, Zuniga ES, Rowehl RH, Park R, Bhalla R, Bialkowska AB, et al. Prostate cancer stem cell-targeted efficacy of a new-generation taxoid, SBT-1214 and novel polyenolic zinc-binding curcuminoid, CMC2.24. PLoS One. 2013; 8: e69884.
Crossref Google Scholar
176

Zhang D, Tang DG, Rycaj K. Cancer stem cells: regulation programs, immunological properties and immunotherapy. Semin Cancer Biol. 2018; 52: 94-106.
Crossref Google Scholar
177

Jachetti E, Mazzoleni S, Grioni M, Ricupito A, Brambillasca C, Generoso L, et al. Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses. Oncoimmunology. 2013; 2: e24520.
Crossref Google Scholar
178

McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, et al. Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. Clin Cancer Res. 2014; 20: 3692-704.
Crossref Google Scholar
179

Codd AS, Kanaseki T, Torigo T, Tabi Z. Cancer stem cells as targets for immunotherapy. Immunology. 2018; 153: 304-14.
Crossref Google Scholar
180

Ugolkov AV, Eisengart LJ, Luan C, Yang XJ. Expression analysis of putative stem cell markers in human benign and malignant prostate: potential stem cell markers in human prostate. Prostate. 2011; 71: 18-25.
Crossref Google Scholar
181

Fan X, Liu S, Su F, Pan Q, Lin T. Effective enrichment of prostate cancer stem cells from spheres in a suspension culture system. Urol Oncol Semin Orig Investig. 2012; 30: 314-8.
Crossref Google Scholar
182

Oktem G, Bilir A, Uslu R, Inan SV, Demiray SB, Atmaca H, et al. Expression profiling of stem cell signaling alters with spheroid formation in CD133high/CD44high prostate cancer stem cells. Oncol Lett. 2014; 7: 2103-9.
Crossref Google Scholar
183

Kerr BA, Miocinovic R, Smith AK, West XZ, Watts KE, Alzayed AW, et al. CD117+ cells in the circulation are predictive of advanced prostate cancer. Oncotarget. 2015; 6: 1889-97.
Crossref Google Scholar
184

Wiesner C, Nabha SM, Bonfil RD, Santos EBD, Yamamoto H, Meng H, et al. C-Kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. Neoplasia. 2008; 10: 996-1003.
Crossref Google Scholar
185

Ricci E, Mattei E, Dumontet C, Eaton CL, Hamdy F, van der Pluije G, et al. Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression: cancer stem cell markers and metastasis progression. Prostate. 2013; 73: 1738-46.
Crossref Google Scholar
186

Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005; 65: 10946-51.
Crossref Google Scholar
187

Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J. 2004; 18: 1240-2.
Crossref Google Scholar
188

Dubrovska A, Elliott J, Salamone RJ, Telegeev GD, Stakhovsky AE, Schepotin IB, et al. CXCR4 expression in prostate cancer progenitor cells. PLoS One. 2012; 7: e31226.
Crossref Google Scholar
189

Domanska UM, Timmer-Bosscha H, Nagengast WB, Oude Munnink TH, Kruizinga RC, Ananias HJK, et al. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia. 2012; 14: 709-18.
Crossref Google Scholar
190

Jiao J, Hindoyan A, Wang S, Tran LM, Goldstein AS, Lawson D, et al. Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells. PLoS One. 2012; 7: e42564.
Crossref Google Scholar
191

An Y, Ongkeko WM. ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol. 2009; 5: 1529-42.
Crossref Google Scholar
192

van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzmán-Ramírez N, et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res. 2010; 70: 5163-73.
Crossref Google Scholar
193

Cojoc M, Mäbert K, Muders MH, Dubrovska A. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Semin Cancer Biol. 2015; 31: 16-27.
Crossref Google Scholar
194

Hoogland AM, Verhoef EI, Roobol MJ, Schröder FH, Wildhagen MF, van der Kwast TH, et al. Validation of stem cell markers in clinical prostate cancer: α6-Integrin is predictive for non-aggressive disease: stem cell markers in prostate cancer. Prostate. 2014; 74: 488-96.
Crossref Google Scholar
195

Li K, Liu C, Zhou B, Bi L, Huang H, Lin T, et al. Role of EZH2 in the growth of prostate cancer stem cells isolated from LNCaP cells. Int J Mol Sci. 2013; 14: 11981-93.
Crossref Google Scholar
196

Matsika A, Srinivasan B, Day C, Mader SA, Margaret Kiernan D, Broomfield A, et al. Cancer stem cell markers in prostate cancer: an immunohistochemical study of ALDH1, SOX2 and EZH2. Pathology (Phila). 2015; 47: 622-8.
Crossref Google Scholar
197

Trerotola M, Ganguly KK, Fazli L, Fedele C, Lu H, Dutta A, et al. Trop-2 is upregulated in invasive prostate cancer and displaces FAK from focal contacts. Oncotarget. 2015; 6: 14318-28.
Crossref Google Scholar
198

Garraway IP, Sun W, Tran CP, Perner S, Zhang B, Goldstein AS, et al. Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo: human prostate sphere-forming cells. Prostate. 2010; 70: 491-501.
Crossref Google Scholar
199

Germann M, Wetterwald A, Guzmán-Ramirez N, van der Pluijm G, Culig Z, Cecchini MG, et al. Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells. 2012; 30: 1076-86.
Crossref Google Scholar
Cancer Biology & Medicine
Volume 20 Issue 6,
June 2023
Pages 401-420
DOI: 10.20892/j.issn.2095-3941.2022.0714
Cite this article:
Banerjee P, Kapse P, Siddique S, et al. Therapeutic implications of cancer stem cells in prostate cancer. Cancer Biology & Medicine, 2023, 20(6): 401-420. https://doi.org/10.20892/j.issn.2095-3941.2022.0714

190

Views

8

Downloads

2

Crossref

7

Web of Science

7

Scopus

Altmetrics
Received: 18 November 2022
Accepted: 12 April 2023
Published: 05 June 2023
©2023 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License
Return